崑崙萬維(300418.SZ):標的資產完成過户 香港萬維持Opera 53.88%的股權
格隆匯 1 月 13日丨崑崙萬維(300418.SZ)公佈,截至此公吿日,此次交易所涉及的標的資產已完成過户手續。
截至公吿日,香港萬維已經按照此次交易相關協議的約定,於2021年1月8日向KFH指定的銀行賬户支付了全部股權轉讓價款8014.5萬美元(約合53963.23萬元人民幣)。
截至公吿日,交易各方完成了此次交易協議中約定的交割程序。根據開曼律師就此次交易實施情況出具的法律意見書,KFH持有的Opera在外流通股份的8.47%的股份已過户至香港萬維並完成變更登記手續,香港萬維持有Opera 53.88%的股權,Opera成為公司全資子公司的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.